This site is intended for Healthcare Professionals only.

PDA supports pharmacists impacted by Integrated Care Systems

Date:

Share post:

The Pharmacists’ Defence Association (PDA) is supporting pharmacists in England whose employment has been impacted by the creation of new NHS structures.

As a result of the 2022 Health and Care Act, Integrated Care Systems (ICSs) were established in England, and Clinical Commissioning Groups (CCGs) were closed on 1 July 2022. Each of the ICSs includes two key parts: an Integrated Care Board (ICB) and an Integrated Care Partnership (ICP).

The association said: “The previous structures in England, established by the Health and Social Care Act 2012, originally had over 200 clinical commissioning groups. This number had reduced over recent years via mergers.”

“However, this latest shift to just 42 commissioning entities means a significant change to significantly larger geographies and populations covered by each ICS. Although each ICS and its activity can be subdivided into ‘places’, and within places into ‘neighbourhoods’, it is at the ICS level that the employer is formed.”

“Whereas CCGs previously employed many local health professionals, including pharmacists, the new arrangements mean that ICBs are now that employer. The PDA is supporting members who have contacted its Service Centre about the impact of these changes.”

The association is also providing members with help and advice on re-organisation, role changes, TUPE transfers, and assisting members with finding alternate jobs in the employer.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...